CytomX Therapeutics (NASDAQ:CTMX) Sees Large Volume Increase After Analyst Upgrade

CytomX Therapeutics, Inc. (NASDAQ:CTMX) shares saw an uptick in trading volume on Wednesday after Jefferies Financial Group raised their price target on the stock from $8.00 to $16.00. Jefferies Financial Group currently has a buy rating on the stock. 9,058,429 shares were traded during trading, an increase of 56% from the previous session’s volume of 5,799,974 shares.The stock last traded at $4.9640 and had previously closed at $5.45.

A number of other research firms also recently weighed in on CTMX. Guggenheim upped their price target on shares of CytomX Therapeutics from $10.00 to $15.00 and gave the stock a “buy” rating in a research note on Wednesday. Oppenheimer reissued an “outperform” rating and set a $12.00 price objective on shares of CytomX Therapeutics in a research report on Monday. Cantor Fitzgerald boosted their target price on CytomX Therapeutics from $6.00 to $10.00 and gave the company an “overweight” rating in a research note on Wednesday, February 4th. HC Wainwright upped their target price on CytomX Therapeutics from $10.00 to $17.00 and gave the stock a “buy” rating in a research report on Monday. Finally, Wedbush raised their price target on CytomX Therapeutics from $6.00 to $11.00 and gave the stock an “outperform” rating in a research note on Tuesday. Nine research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $12.56.

Key Headlines Impacting CytomX Therapeutics

Here are the key news stories impacting CytomX Therapeutics this week:

• Positive Sentiment: Multiple analysts raised price targets or upgraded the stock — Guggenheim raised its target to $15 and put a Buy on CTMX, Wedbush raised its target to $11 with an Outperform, and JPMorgan issued an upgrade — these notes signal continued institutional interest and provide upside conviction for the shares. Benzinga JPMorgan Upgrade
• Positive Sentiment: Clinical catalyst: strong Phase I Varseta‑M data in metastatic colorectal cancer previously triggered a rally and underpins investor optimism about the pipeline’s upside. Zacks
• Neutral Sentiment: Company posted its Q4 results presentation (useful for diligence), providing the latest formal disclosures on operations and pipeline progress. Investors should review the deck for cash runway details and program timelines. Q4 Presentation
• Negative Sentiment: Dilutive equity financing: CytomX priced a $250M offering at $5.30/share (≈46M shares plus pre‑funded warrants). The sale increases share count materially and is the primary near‑term headwind pressuring the stock. Offering Filing
• Negative Sentiment: HC Wainwright lowered near‑term EPS forecasts substantially (Q1–Q4 2026 and FY2026 cuts) even while maintaining a Buy and a $17 target; the reduced estimates highlight expected near‑term cash burn and push downside to short‑term earnings expectations. Analyst Note
• Negative Sentiment: Recent quarter missed consensus on EPS and revenue (reported March 16), underscoring why the company sought additional capital and why near‑term profitability looks distant. Earnings Coverage

Institutional Investors Weigh In On CytomX Therapeutics

A number of large investors have recently bought and sold shares of the business. Orbimed Advisors LLC acquired a new position in CytomX Therapeutics during the second quarter worth $19,208,000. Commodore Capital LP bought a new position in CytomX Therapeutics during the second quarter valued at about $17,462,000. Perceptive Advisors LLC acquired a new stake in shares of CytomX Therapeutics in the second quarter worth about $15,876,000. Franklin Resources Inc. acquired a new stake in shares of CytomX Therapeutics in the second quarter worth about $13,096,000. Finally, Vivo Capital LLC bought a new stake in shares of CytomX Therapeutics during the 2nd quarter worth about $13,096,000. 67.77% of the stock is currently owned by institutional investors.

CytomX Therapeutics Stock Performance

The company has a market cap of $748.84 million, a P/E ratio of -110.00 and a beta of 2.44. The firm has a 50 day moving average price of $5.27 and a 200-day moving average price of $4.10.

CytomX Therapeutics (NASDAQ:CTMX) last issued its quarterly earnings data on Monday, March 16th. The biotechnology company reported ($0.22) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.14). CytomX Therapeutics had a negative net margin of 22.79% and a negative return on equity of 19.77%. The company had revenue of $0.66 million during the quarter, compared to the consensus estimate of $7.33 million. On average, sell-side analysts forecast that CytomX Therapeutics, Inc. will post -0.05 EPS for the current fiscal year.

CytomX Therapeutics Company Profile

CytomX Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of next-generation therapeutics based on its proprietary Probody® platform. The company engineers masked antibody prodrugs that remain inactive in healthy tissue but are selectively activated in the tumor microenvironment. This approach is designed to enhance the safety and tolerability of antibody-based therapies, particularly those targeting immuno-oncology pathways.

At the core of CytomX’s pipeline is Pacmilimab (CX-072), an anti–PD-L1 Probody therapeutic currently undergoing clinical evaluation for multiple solid tumor indications.